American depositary receipts of Takeda Pharmaceutical Co.
4502,
TAK,
rose more than 1% in the extended session Tuesday after the Japan-based company said its dengue vaccine got the recommendation from an immunizations advisory board with the World Health Organization. The WHO will consider the recommendation in the coming weeks, the company said. Mosquito-borne dengue is endemic in more than 100 countries and causes an estimated 390 million infections each year, Takeda said. Dengue is also a “leading cause” of fever among travelers returning from Latin America, the Caribbean and Southeast Asia, the company said. Takeda’s ADRs ended the regular trading day down 0.7%.
